Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
Abstract Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical outc...
Guardado en:
Autores principales: | Andrea R. Di Sebastiano, Andrew Deweyert, Simon Benoit, Erin Iredale, Hu Xu, Cleusa De Oliveira, Eugene Wong, Susanne Schmid, Matthew O. Hebb |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f05a2ae04fe4064a4a868d526562962 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Maximilian A. Kirchner, et al.
Publicado: (2021) -
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
por: Giulia Agliardi, et al.
Publicado: (2021) -
Trial watch: intratumoral immunotherapy
por: Juliette Humeau, et al.
Publicado: (2021) -
Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Teresa Neeman, et al.
Publicado: (2021) -
A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
por: Klapproth AP, et al.
Publicado: (2020)